作者
Michael P Flaherty, Jeffrey W Moses, Ralf Westenfeld, Igor Palacios, William W O'Neill, Theodore L Schreiber, Michael J Lim, Amir Kaki, Ioana Ghiu, Roxanna Mehran
发表日期
2020/5/1
期刊
Catheterization and Cardiovascular Interventions
卷号
95
期号
6
页码范围
1111-1121
出版商
John Wiley & Sons, Inc.
简介
Background
Protection against acute kidney injury (AKI) has been reported with the use of Impella during high‐risk percutaneous coronary intervention (HR‐PCI). We sought to evaluate this finding by determining the occurrence of AKI during Impella‐supported HR‐PCI in patients from the Global cVAD Study and compare this incidence with their calculated AKI risk at baseline.
Methods and Results
In this prospective, multicenter study, we enrolled 314 consecutive patients. We included 223 patients that underwent nonemergent HR‐PCI supported with Impella 2.5 or Impella CP and excluded those requiring hemodialysis prior to HR‐PCI (19) and those with insufficient data (72). The primary outcome was AKI postprocedurally at 48 hr versus the predicted risk of AKI according to Mehran risk score. Logistic regression analysis determined predictors of AKI. Overall, 4.9% (11) of Impella‐supported patients …
学术搜索中的文章
MP Flaherty, JW Moses, R Westenfeld, I Palacios… - Catheterization and Cardiovascular Interventions, 2020